EUVIMEDEUVIMED entdecken
Open Access

Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8 + T cell function in lung cancer

Xuyu Gu iD, Yifei Zhu iD, Li Xu, Xinnan Xu iD, Kaiqi Jin iD, William C Cho iD, Qiyu Fang iD

Science Advances · 2026

DOI: 10.1126/sciadv.aef1694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Xuyu Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai Pulmonary Hospital, School of medicine, Tongji University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Lung Neoplasms, CD8-Positive T-Lymphocytes, Extracellular Matrix, Protein-Lysine 6-Oxidase. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Science Foundation of Shanghai, Tongji University Independent and Original Basic Research Project, Youth Found of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular matrix (ECM) stiffness is known to impair T cell function, yet the underpinning molecular cascade remains undefined. This paper investigates the role of lysyl oxidase–like 4 (LOXL4) in ECM stiffening and CD8 + T cell function in lung cancer. Loxl4 knockout and mouse recombinant LOXL4 protein systems, along with Piezo1 , Ybx1 , Acly , and Kat2a conditional knockout mouse models were established. ECM stiffness was measured by atomic force microscopy, and T cell exhaustion markers were analyzed using flow cytometry. RNA sequencing, ATAC-seq, CUT&Tag, chromatin immunoprecipitation–quantitative polymerase chain reaction, and luciferase assays were used to explore the underlying molecular mechanisms. Molecular docking was performed to explore Food and Drug Administration–approved agents targeting LOXL4. The results demonstrated that tumor-derived LOXL4 stiffened the ECM, which activates the mechanosensor Piezo1 in CD8 + T cells, triggering Ca 2+ influx and downstream FAK1-YAP1 signaling. Nuclear YAP1 transactivated YBX1, which recruited the metabolic enzyme ACLY and the histone acetyltransferase KAT2A to exhaustion gene loci, epigenetically reinforcing terminal exhaustion. Conditional knockout of Piezo1 , Ybx1 , Acly , and Kat2a in murine CD8 + T cells abolished stiffness-induced exhaustion and suppressed tumor growth. Acetyldigoxin was identified as a high-affinity LOXL4 inhibitor. It softened the ECM, disrupted the mechanosignaling-epigenetic axis, reversed CD8 + T cell exhaustion, and synergized with anti–PD-1 blockade to achieve durable tumor regression. In conclusion, this study uncovers a mechanotransduction-to-epigenetic pathway where LOXL4-driven matrix stiffening induces CD8 + T cell exhaustion. Repurposing acetyldigoxin as a LOXL4-targeted therapy offers a promising clinical strategy to overcome ECM-mediated immunotherapy resistance in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCD8-Positive T-LymphocytesExtracellular MatrixProtein-Lysine 6-OxidaseAnimalsMiceHumansMice, KnockoutT-Cell ExhaustionYAP-Signaling ProteinsMolecular Docking Simulation

Substanzen

Protein-Lysine 6-OxidaseYAP-Signaling ProteinsLOXL4 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Shanghai Pulmonary Hospital, School of medicine, Tongji University, Shanghai 200433, China.
  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of medicine, Tongji University, Shanghai 200433, China.
  • Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

ORCID-Profile: Xuyu Gu, Yifei Zhu, Xinnan Xu, Kaiqi Jin, William C Cho, Qiyu Fang

Förderung

  • Natural Science Foundation of Shanghai
  • Tongji University Independent and Original Basic Research Project
  • Youth Found of the National Natural Science Foundation of China
  • China Health & Medical Development Foundation

Zitieren

APA

Gu, X., Zhu, Y., Xu, L., Xu, X., Jin, K., Cho, W. C., & Fang, Q. (2026). Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8 + T cell function in lung cancer. Science Advances. https://doi.org/10.1126/sciadv.aef1694

Vancouver

Gu X, Zhu Y, Xu L, Xu X, Jin K, Cho WC, et al. Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8 + T cell function in lung cancer. Science Advances. 2026. doi:10.1126/sciadv.aef1694

BibTeX
@article{Gu2026,
  author = {Gu, Xuyu and Zhu, Yifei and Xu, Li and Xu, Xinnan and Jin, Kaiqi and Cho, William C and Fang, Qiyu},
  title = {Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8 + T cell function in lung cancer},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aef1694}
}
Kostenlos starten →